Cancer Research CTRC-AACR San Antonio Breast Cancer Symposium
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 17, 11-14, January 1, 1957]
© 1957 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lippman, S. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lippman, S. M.

The Growth-inhibitory Action of Heparin on the Ehrlich Ascites Tumor in Mice*

Sister Muriel Lippman, S.S.J.{dagger}

( Nazareth College of Rochester, Rochester, New York)

Heparin acts as a mitotic inhibitor on the Ehrlich ascites tumor in vivo, as shown by a highly significant decrease in the mitotic index following the single but not the repeated injections. This reduction in the mitotic index is reflected by tumor regression to the extent of a 40–50 per cent decrease in tumor volume. The experimental conditions employed produced no effect on the survival time of the treated animals. It is suggested that heparin exerts its effects directly on the tumor cells rather than indirectly following hemorrhage.

* The present investigation was carried out at the University of Pennsylvania, Philadelphia, Pa.; the Marine Biological Laboratory, Woods Hole, Mass.; and at Nazareth College of Rochester, Rochester, N.Y.

Experimental work done at the University of Pennsylvania and at the Marine Biological Laboratory was supported by the United States Public Health Grants C411C6 and C411C7 under the direction of Dr. L. V. Heilbrunn, and was submitted in partial fulfillment of the requirements for the degree of Master of Science.

Lederle Laboratories, Pearl River, N.Y., and Upjohn Co., Kalamazoo, Michigan, supplied the heparin used for experimental purposes.

{dagger} The author wishes to express her gratitude to Dr. L. V. Heilbrunn for suggesting the problem, to Sister Francis Solano, S.S.J., Chairman of the Department of Biology, for facilitating the progress of the work at Nazareth College, and to Sister M. Jamesetta, S.S.J., for her assistance with the manuscript.

Received 6/ 5/56.





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1957 by the American Association for Cancer Research.